Tempus AI disclosed a package of oncology and neurology data agreements that could produce $192.5 million in cash payments over roughly five years. The company announced the expanded Bristol Myers Squibb relationship on October 23, 2026, while its SEC filing separates the underlying agreements signed on October 14 and October 22.
Agreements Set a $192.5M Payment Framework
Tempus said in its October 23 announcement that Bristol Myers Squibb will license multimodal oncology data through 2031 and use the Tempus Lens platform. The arrangement is designed to support drug-target discovery and therapeutic development, but the company did not present the total value in the press release.
The company’s Form 8-K provides the financial detail. It lists $137.5 million in fixed payments under the oncology statement of work and up to $55 million under the Pathos neurology order, for an aggregate of $192.5 million over approximately five years.
| Agreement | Potential payments | Term or delivery basis |
|---|---|---|
| BMS oncology data and services | $137.5M fixed | Through Dec. 31, 2031 |
| Pathos neurology data and agent tool | Up to $55M | 500,000 records over five years |
| Total framework | $192.5M | Approximately five years |
How the Oncology and Neurology Data Deals Work
Bristol Myers Squibb will receive de-identified oncology records, Tempus Lens access and related analysis services. The data can also be used with Pathos’s Foundry drug-development platform, linking clinical information with AI-assisted research workflows.
Under the neurology order, Tempus plans to deliver 100,000 records annually covering Alzheimer’s disease and other specified conditions. Pathos will pay $100 per delivered record, up to $50 million, plus $5 million for record-update availability. That delivery condition means the full amount is not guaranteed.
The structure extends the use of clinical AI beyond diagnosis. Fusion’s coverage of Microsoft’s sequential diagnosis research examined the testing side, while the Bolt-Prana transaction and Zai Lab financing show how data, drug pipelines and capital increasingly intersect.
What Investors Should Watch
Investors should distinguish contracted payment schedules from recognized revenue and cash collection. The oncology agreement allows termination with 12 months’ notice and a substantial termination fee, while the neurology fees depend on records actually delivered.
The filing also identifies a related-party issue because Tempus and Pathos have overlapping executive leadership and equity ownership. A special committee of disinterested Tempus directors approved the Pathos arrangements under the company’s related-person transaction policy.
This article is for informational purposes only and does not constitute financial advice. Investors should review Tempus filings, revenue-recognition disclosures and execution risks before making decisions.
Sharron Kendi
Sharron Kendi is a seasoned crypto market analyst and writer with over three years of experience decoding blockchain trends, price movements, and market dynamics. She holds a Bachelor’s Degree in Commerce (Finance) from Kenyatta University, blending a solid academic foundation with a sharp eye for technical analysis and a deep understanding of on-chain data. Her work delivers clear, data-driven insights that empower investors to navigate the fast-evolving digital asset space with confidence.
